{"id":58725,"date":"2026-03-04T13:09:08","date_gmt":"2026-03-04T05:09:08","guid":{"rendered":"https:\/\/flcube.com\/?p=58725"},"modified":"2026-03-04T13:09:09","modified_gmt":"2026-03-04T05:09:09","slug":"teva-secures-400m-blackstone-funding-for-duvakitug-tl1a-antibody-advances-in-ibd-phase-iii","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58725","title":{"rendered":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III"},"content":{"rendered":"\n<p><strong>Teva Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE:\u202fTEVA<\/a>)<\/strong> and <strong>Blackstone Life Sciences (BXLS)<\/strong> announced a <strong>$400\u202fmillion strategic funding agreement<\/strong> over <strong>four years<\/strong> to support <strong>clinical development of duvakitug<\/strong>, a <strong>human monoclonal antibody targeting TL1A<\/strong> for <strong>inflammatory bowel disease (IBD)<\/strong>. The financing enables <strong>continued Phase III investment<\/strong> while preserving Teva&#8217;s <strong>co\u2011development and co\u2011commercialization partnership with Sanofi<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Teva Pharmaceuticals (NYSE:\u202fTEVA)<\/td><\/tr><tr><td><strong>Investor<\/strong><\/td><td>Blackstone Life Sciences (BXLS)<\/td><\/tr><tr><td><strong>Funding Amount<\/strong><\/td><td><strong>USD\u202f400\u202fmillion<\/strong> (over 4 years)<\/td><\/tr><tr><td><strong>Purpose<\/strong><\/td><td>Ongoing and future duvakitug development costs<\/td><\/tr><tr><td><strong>Milestone Payment<\/strong><\/td><td>Payable to BXLS upon FDA approval of duvakitug<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Additional payments to BXLS post\u2011approval<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Low single\u2011digit on worldwide sales to BXLS<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-duvakitug\">Drug Profile \u2013 Duvakitug<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Class<\/strong><\/td><td>Human monoclonal antibody<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>TL1A (TNFSF15)<\/strong> \u2013 TNF\u2011like ligand 1A<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks TL1A\u2011mediated inflammation and fibrosis pathways<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Ulcerative colitis (UC) + Crohn&#8217;s disease (CD)<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td><strong>Phase III<\/strong> ongoing<\/td><\/tr><tr><td><strong>Phase 2b Data<\/strong><\/td><td>Clinically meaningful <strong>durable efficacy<\/strong> in UC and CD maintenance<\/td><\/tr><tr><td><strong>Partnership<\/strong><\/td><td>Co\u2011development\/co\u2011commercialization with <strong>Sanofi<\/strong> (2023 agreement)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TL1A Target Validation:<\/strong> TL1A is an <strong>emerging IBD target<\/strong> with <strong>fibrosis\u2011modulating properties<\/strong>\u2014differentiating from anti\u2011TNF and anti\u2011integrin therapies; duvakitug&#8217;s <strong>Phase 2b durability<\/strong> supports <strong>best\u2011in\u2011class potential<\/strong>.<\/li>\n\n\n\n<li><strong>Non\u2011Dilutive Financing:<\/strong> The <strong>$400\u202fmillion BXLS facility<\/strong> provides <strong>development capital without equity dilution<\/strong>, preserving Teva shareholder value while advancing a <strong>potential blockbuster asset<\/strong>.<\/li>\n\n\n\n<li><strong>Sanofi Partnership Synergy:<\/strong> The <strong>2023 co\u2011development agreement<\/strong> with Sanofi\u2014<strong>independent of BXLS financing<\/strong>\u2014ensures <strong>global commercial infrastructure<\/strong> and <strong>shared Phase III costs<\/strong>, de\u2011risking Teva&#8217;s investment.<\/li>\n\n\n\n<li><strong>IBD Market Opportunity:<\/strong> UC and CD represent <strong>$20\u202fbillion+ combined market<\/strong> with significant unmet need for <strong>fibrosis\u2011targeting therapies<\/strong>; duvakitug addresses <strong>stricturing and penetrating disease complications<\/strong> not resolved by existing biologics.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>TL1A Competitive Landscape<\/strong><\/td><td>Prometheus Biosciences (acquired by Merck) leads with PRA\u2011023 in Phase III; Teva\/Sanofi&#8217;s duvakitug competes for second\u2011to\u2011market position<\/td><\/tr><tr><td><strong>IBD Fibrosis Unmet Need<\/strong><\/td><td>30\u201140% of Crohn&#8217;s patients develop strictures; no approved anti\u2011fibrotic therapies; TL1A inhibition addresses this gap<\/td><\/tr><tr><td><strong>Blackstone Life Sciences Strategy<\/strong><\/td><td>BXLS&#8217;s $400M commitment reflects confidence in TL1A mechanism and Teva\/Sanofi execution; follows similar structured financing deals (e.g., Alnylam, Intellia)<\/td><\/tr><tr><td><strong>Teva Pipeline Transformation<\/strong><\/td><td>Duvakitug represents Teva&#8217;s <strong>innovation pivot<\/strong> beyond generics and Austedo; successful Phase III could re\u2011rate valuation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III enrollment, regulatory submission timelines, and commercial potential for duvakitug. Actual results may differ due to risks including competitive TL1A program advancement, Sanofi partnership execution, and long\u2011term safety monitoring in chronic IBD use.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3616,1072,1071],"class_list":["post-58725","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-blackstone-life-sciences","tag-nyse-teva","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva&#039;s co\u2011development and co\u2011commercialization partnership with Sanofi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58725\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III\" \/>\n<meta property=\"og:description\" content=\"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva&#039;s co\u2011development and co\u2011commercialization partnership with Sanofi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58725\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T05:09:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T05:09:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III\",\"datePublished\":\"2026-03-04T05:09:08+00:00\",\"dateModified\":\"2026-03-04T05:09:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Blackstone Life Sciences\",\"NYSE: TEVA\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58725#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58725\",\"name\":\"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-04T05:09:08+00:00\",\"dateModified\":\"2026-03-04T05:09:09+00:00\",\"description\":\"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva's co\u2011development and co\u2011commercialization partnership with Sanofi.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58725\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58725#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III - Insight, China&#039;s Pharmaceutical Industry","description":"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva's co\u2011development and co\u2011commercialization partnership with Sanofi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58725","og_locale":"en_US","og_type":"article","og_title":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III","og_description":"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva's co\u2011development and co\u2011commercialization partnership with Sanofi.","og_url":"https:\/\/flcube.com\/?p=58725","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T05:09:08+00:00","article_modified_time":"2026-03-04T05:09:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58725#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58725"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III","datePublished":"2026-03-04T05:09:08+00:00","dateModified":"2026-03-04T05:09:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58725"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Blackstone Life Sciences","NYSE: TEVA","Teva Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58725#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58725","url":"https:\/\/flcube.com\/?p=58725","name":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-04T05:09:08+00:00","dateModified":"2026-03-04T05:09:09+00:00","description":"Teva Pharmaceuticals (NYSE:\u202fTEVA) and Blackstone Life Sciences (BXLS) announced a $400\u202fmillion strategic funding agreement over four years to support clinical development of duvakitug, a human monoclonal antibody targeting TL1A for inflammatory bowel disease (IBD). The financing enables continued Phase III investment while preserving Teva's co\u2011development and co\u2011commercialization partnership with Sanofi.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58725#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58725"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58725#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teva Secures $400M Blackstone Funding for Duvakitug \u2013 TL1A Antibody Advances in IBD Phase III"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58725"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58725\/revisions"}],"predecessor-version":[{"id":58726,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58725\/revisions\/58726"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}